GlassScriptPhysician profile
Laura K Stevenson
NPI 1437116639
$10,243.21
in general payments reported to CMS, 2019-2025
25 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,010 · 2022: $1,457 · 2023: $1,885 · 2024: $2,479 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,378 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,378.14 |
| Education | $398.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $2,381.14 | 2021-2024 | |
| Genzyme Corporation | $1,558.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,087.48 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $774.57 | 2022-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $709.06 | 2021-2025 | |
| Lilly USA, LLC | $633.24 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $619.66 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $392.06 | 2022-2025 | Opzelura |
| Pfizer INC. | $340.16 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $332.50 | 2023-2025 | Zoryve |
| Epi Health, LLC | $260.45 | 2021-2022 | |
| Amgen INC. | $232.71 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $198.24 | 2022-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $169.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $112.43 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $110.72 | 2022-2024 | Vtama |
| Organon LLC | $73.79 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.59 | 2021-2024 | Arazlo, Cabtreo, Jublia |
| Boston Scientific Corporation | $44.71 | 2021 | |
| Organogenesis INC. | $42.00 | 2024 | |
| Galderma Laboratories, L.P. | $37.08 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.08 | 2022 | |
| Botanix Sb INC | $20.84 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $19.21 | 2025 | Ycanth |
| Mayne Pharma Commercial LLC | $18.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.